SELECT FROM MENU

Therapy Area
Drug Classes

       Disease Area

All Sessions

All Sessions

All Sessions

Resectable NSCLC

All Sessions

Metastatic NSCLC

All Sessions

SCLC

All Sessions

Biomarkers

       Drug Class

Targeted Therapies

Targeted Therapies

Immuno-therapies

Immuno-therapies

Antibody-Drug Conjugates

Antibody-Drug Conjugates

Therapy Area
Drug Classes

       Disease Area

All Sessions

All Sessions

All Sessions

Resectable NSCLC

All Sessions

Metastatic NSCLC

All Sessions

SCLC

All Sessions

Biomarkers

       Drug Class

Targeted Therapies

Targeted Therapies

Immuno-therapies

Immuno-therapies

Antibody-Drug Conjugates

Antibody-Drug Conjugates

All
FEATURED
ILCS
Webinars
Articles

       Industry Sponsored

Featured Sessions

Sep 26 2025

RESHAPING APPROACHES IN SCLC WITH THE LATEST ADVANCES IN LS- AND ES-DISEASE

} 34 min

Read More
Sep 26 2025

LATEST OPTIONS FOR NON-ONCOGENE ADDICTED METASTATIC NSCLC IN FRONTLINE AND BEYOND

} 32 min

Read More
Sep 26 2025

THE ROLE OF IO ADDED TO CHEMORADIATION IN UNRESECTABLE STAGE III NSCLC

} 28 min

Read More
Sep 26 2025

TAILORING IO IN RES. NSCLC: PERSONALIZED APPROACHES FOR IMPROVED OUTCOMES

} 36 min

Read More
Sep 26 2025

THE ADC REVOLUTION IN LUNG CANCER: NEW TARGETS, NEW OPPORTUNITIES

} 27 min

Read More
Sep 26 2025

DEBATE: WHICH IS THE BETTER CHOICE IN EGFR+ METASTATIC NSCLC?

} 31 min

Read More
Sep 26 2025

ACTIONABLE GENOMIC ALTERATIONS – INCLUDING HER2 AND MET

} 26 min

Read More
Sep 26 2025

TARGETING EGFR AND ALK IN NSCLC

} 26 min

Read More

       From Our Annual Summit

ILCS Sessions

Sep 26 2025

RESHAPING APPROACHES IN SCLC WITH THE LATEST ADVANCES IN LS- AND ES-DISEASE

} 34 min
Sep 26 2025

LATEST OPTIONS FOR NON-ONCOGENE ADDICTED METASTATIC NSCLC IN FRONTLINE AND BEYOND

} 32 min
Sep 26 2025

THE ROLE OF IO ADDED TO CHEMORADIATION IN UNRESECTABLE STAGE III NSCLC

} 28 min
Sep 26 2025

TAILORING IO IN RES. NSCLC: PERSONALIZED APPROACHES FOR IMPROVED OUTCOMES

} 36 min
Sep 26 2025

THE ADC REVOLUTION IN LUNG CANCER: NEW TARGETS, NEW OPPORTUNITIES

} 27 min
Sep 26 2025

DEBATE: WHICH IS THE BETTER CHOICE IN EGFR+ METASTATIC NSCLC?

} 31 min
Sep 26 2025

ACTIONABLE GENOMIC ALTERATIONS – INCLUDING HER2 AND MET

} 26 min
Sep 26 2025

TARGETING EGFR AND ALK IN NSCLC

} 26 min

       Expert Insights

Webinars

Lung Cancer Review by Solange Peters, Martin Reck, Charles Rudin
Dec 18 2025

2025 Approvals & Highlights

} 1 h 49 min
Targeted Therapies by Oliver Gautschi, Jarushka Naidoo, Nicolas Girard
Jul 10 2025

Targeted Therapies in NSCLC

} 1h 30 min
IO in NSCLC by Solange Peters, Jordi Remon, Patrick Forde
Jun 25 2025

Immunotherapies in NSCLC

} 1h 47 min
SCLC by Solange Peters, Giannis Mountzios, Jacob Sands
Jun 17 2025

Small Cell Lung Cancer

} 1h 35 min

       The Reading Room

Articles & Research

Apr 15 2026
Uncategorized

Targeted Therapies in Metastatic NSCLC: Reshaping First-Line Choice

Five next-generation TKIs have rewritten first-line choice in driver-positive metastatic NSCLC. This update distils which biomarker matters, when CNS coverage drives the pick, and where the field is heading ...
Mar 22 2026
Uncategorized

ADCs in Small Cell Lung Cancer: An Emerging Class

Antibody-drug conjugates are arriving in SCLC after a decade of failed cytotoxics. Three platforms — DLL3, B7-H3, and SEZ6 — now have phase-2 readouts. This update...
Sep 20 2024
OncoNews

Bridging The Gap In Thoracic Oncology: What To Expect From The 6th ILCS

[et_pb_section fb_built ="1" admin_label ="section" _builder_version ="4.27.4" background_color ="#f5f8fb" positioning ="none" z_index ="0" custom_padding ="0px||0px|||" global_colors_info ="{}" theme_builder_area ="post_content"][et_pb_row admin_label ="row" _builder_version ="4.27.4" background_size ="initial" background_position ="top_left" background_repeat ="repeat" width...

       Industry Sponsored

Featured Sessions

Sep 26 2025

RESHAPING APPROACHES IN SCLC WITH THE LATEST ADVANCES IN LS- AND ES-DISEASE

} 34 min

Read More
Sep 26 2025

LATEST OPTIONS FOR NON-ONCOGENE ADDICTED METASTATIC NSCLC IN FRONTLINE AND BEYOND

} 32 min

Read More
Sep 26 2025

THE ROLE OF IO ADDED TO CHEMORADIATION IN UNRESECTABLE STAGE III NSCLC

} 28 min

Read More
Sep 26 2025

TAILORING IO IN RES. NSCLC: PERSONALIZED APPROACHES FOR IMPROVED OUTCOMES

} 36 min

Read More
Sep 26 2025

THE ADC REVOLUTION IN LUNG CANCER: NEW TARGETS, NEW OPPORTUNITIES

} 27 min

Read More
Sep 26 2025

DEBATE: WHICH IS THE BETTER CHOICE IN EGFR+ METASTATIC NSCLC?

} 31 min

Read More
Sep 26 2025

ACTIONABLE GENOMIC ALTERATIONS – INCLUDING HER2 AND MET

} 26 min

Read More
Sep 26 2025

TARGETING EGFR AND ALK IN NSCLC

} 26 min

Read More

       From Our Annual Summit

ILCS Sessions

Sep 26 2025

RESHAPING APPROACHES IN SCLC WITH THE LATEST ADVANCES IN LS- AND ES-DISEASE

} 34 min
Sep 26 2025

LATEST OPTIONS FOR NON-ONCOGENE ADDICTED METASTATIC NSCLC IN FRONTLINE AND BEYOND

} 32 min
Sep 26 2025

THE ROLE OF IO ADDED TO CHEMORADIATION IN UNRESECTABLE STAGE III NSCLC

} 28 min
Sep 26 2025

TAILORING IO IN RES. NSCLC: PERSONALIZED APPROACHES FOR IMPROVED OUTCOMES

} 36 min
Sep 26 2025

THE ADC REVOLUTION IN LUNG CANCER: NEW TARGETS, NEW OPPORTUNITIES

} 27 min
Sep 26 2025

DEBATE: WHICH IS THE BETTER CHOICE IN EGFR+ METASTATIC NSCLC?

} 31 min
Sep 26 2025

ACTIONABLE GENOMIC ALTERATIONS – INCLUDING HER2 AND MET

} 26 min
Sep 26 2025

TARGETING EGFR AND ALK IN NSCLC

} 26 min

       Expert Insights

Webinars

Lung Cancer Review by Solange Peters, Martin Reck, Charles Rudin
Dec 18 2025

2025 Approvals & Highlights

} 1 h 49 min
Targeted Therapies by Oliver Gautschi, Jarushka Naidoo, Nicolas Girard
Jul 10 2025

Targeted Therapies in NSCLC

} 1h 30 min
IO in NSCLC by Solange Peters, Jordi Remon, Patrick Forde
Jun 25 2025

Immunotherapies in NSCLC

} 1h 47 min
SCLC by Solange Peters, Giannis Mountzios, Jacob Sands
Jun 17 2025

Small Cell Lung Cancer

} 1h 35 min

       The Reading Room

Articles & Research

Apr 15 2026
Uncategorized

Targeted Therapies in Metastatic NSCLC: Reshaping First-Line Choice

Five next-generation TKIs have rewritten first-line choice in driver-positive metastatic NSCLC. This update distils which biomarker matters, when CNS coverage drives the pick, and where the field is heading ...
Mar 22 2026
Uncategorized

ADCs in Small Cell Lung Cancer: An Emerging Class

Antibody-drug conjugates are arriving in SCLC after a decade of failed cytotoxics. Three platforms — DLL3, B7-H3, and SEZ6 — now have phase-2 readouts. This update...
Sep 20 2024
OncoNews

Bridging The Gap In Thoracic Oncology: What To Expect From The 6th ILCS

[et_pb_section fb_built ="1" admin_label ="section" _builder_version ="4.27.4" background_color ="#f5f8fb" positioning ="none" z_index ="0" custom_padding ="0px||0px|||" global_colors_info ="{}" theme_builder_area ="post_content"][et_pb_row admin_label ="row" _builder_version ="4.27.4" background_size ="initial" background_position ="top_left" background_repeat ="repeat" width...

Indication Areas

All Sessions

All Sessions

Resectable NSCLC

Resectable NSCLC

Metastatic Lung Cancer

Metastatic NSCLC

Lung Cancer

SCLC

Biomarkers

Biomarkers & Diagnostics

DRUG CLASSES

Pill

Targeted Therapies

OncoNews

Immunotherapies

Antibody Drug Conjugates

Antibody-Drug Conjugates